Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
![]()
Gladskin is the only healthy option in today’s market which is replete with corticosteroids and ineffective antibiotics for skincare and treatment
Share this Article:
Tweet
|
Company
Micreos
Headquarters
Den Haag, Zuid Holland
Management
Mr. Mark Offerhaus, CEO
Description
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos endolysin technology, for the first time only the unwanted bacteria can be killed - including antibiotic resistant strains - while preserving the beneficial bacteria, essential for our health. Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info